Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial.

MLA

Grebely, Jason, et al. “Elbasvir and Grazoprevir for Hepatitis C Virus Genotype 1 Infection in People with Recent Injecting Drug Use (DARLO-C): An Open-Label, Single-Arm, Phase 4, Multicentre Trial.” Health Science Reports, vol. 3, no. 2, June 2020, pp. 1–10. EBSCOhost, https://doi.org/10.1002/hsr2.151.

APA

Grebely, J., Read, P., Cunningham, E. B., Weltman, M., Matthews, G. V., Dunlop, A., Montebello, M., Martinello, M., Gilliver, R., Marks, P., Applegate, T. L., & Dore, G. J. (2020). Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial. Health Science Reports, 3(2), 1–10. https://doi.org/10.1002/hsr2.151

Chicago

Grebely, Jason, Phillip Read, Evan B. Cunningham, Martin Weltman, Gail V. Matthews, Adrian Dunlop, Mark Montebello, et al. 2020. “Elbasvir and Grazoprevir for Hepatitis C Virus Genotype 1 Infection in People with Recent Injecting Drug Use (DARLO-C): An Open-Label, Single-Arm, Phase 4, Multicentre Trial.” Health Science Reports 3 (2): 1–10. doi:10.1002/hsr2.151.